CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells

Yu,Jian-Hua; Zhong,Xiang-Yu; Zhang,Wei-Guang; Wang,Zhi-Dong; Dong,Qin; Tai,Sheng; Li,Hui; Cui,Yun-Fu

doi:10.3892/or.2011.1617

CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells

Authors:
- Jian-Hua Yu
- Xiang-Yu Zhong
- Wei-Guang Zhang
- Zhi-Dong Wang
- Qin Dong
- Sheng Tai
- Hui Li
- Yun-Fu Cui
View Affiliations

Affiliations: Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin 150086, P.R. China, Department of Biochemistry and Molecular Biology, Basic Medical Science College, Harbin Medical University, Harbin 150081, P.R. China
Published online on: December 30, 2011 https://doi.org/10.3892/or.2011.1617
Pages: 1266-1276

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cyclin-dependent kinase 10 (CDK10) is a member of the Cdc2 family of kinases, and has been demonstrated to be an important determinant of resistance to endocrine therapy for breast cancer. To investigate the expression and possible function of CDK10 in biliary tract cancer (BTC), we systematically examined CDK10 in tissues and cell lines. We found that expression of CDK10 was downregulated in both biliary tract tumors and cell lines. Remarkably, the expression of CDK10 correlated with clinical characteristics. Overexpression or knockdown of CDK10, respectively, inhibited or promoted cell proliferation, colony formation and migration. This suggests that CDK10 functions as a tumor suppressor gene in BTC. Overexpression of CDK10 caused malignant cells to become sensitive to chemotherapy and other hostile environments, suggesting that CDK10 functions to regulate survivability of BTC cells. We investigated the expression of six genes to resolve the mechanism. c-RAF was negatively regulated by CDK10 in both cells and specimens. Our results indicate that CDK10 plays a crucial role in the growth and survivability of biliary tract cancer, and offers a potential therapeutic target for this fatal disease.

View Figures

View References

1	de Groen PC, Gores GJ, LaRusso NF, Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med. 341:1368–1378. 1999.
2	Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004. View Article : Google Scholar : PubMed/NCBI
3	Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314. 2005. View Article : Google Scholar : PubMed/NCBI
4	Nakeeb A, Pitt HA, Sohn TA, et al: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 224:463–475. 1996. View Article : Google Scholar : PubMed/NCBI
5	Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
6	Malhi H and Gores GJ: Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol. 45:856–867. 2006. View Article : Google Scholar : PubMed/NCBI
7	Jarnagin WR and Shoup M: Surgical management of cholangiocarcinoma. Semin Liver Dis. 24:189–199. 2004. View Article : Google Scholar
8	Li S, MacLachlan TK, De Luca A, Claudio PP, Condorelli G and Giordano A: The cdc-2-related kinase, PISSLRE, is essential for cell growth and acts in G2 phase of the cell cycle. Cancer Res. 55:3992–3995. 1995.PubMed/NCBI
9	Kasten M and Giordano A: Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene. 20:1832–1838. 2001. View Article : Google Scholar : PubMed/NCBI
10	Iorns E, Turner NC, Elliott R, et al: Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 13:91–104. 2008. View Article : Google Scholar : PubMed/NCBI
11	Leman ES, Magheli A, Yong KM, Netto G, Hinz S and Getzenberg RH: Identification of nuclear structural protein alterations associated with seminomas. J Cell Biochem. 108:1274–1279. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kanno N, Lesage G, Phinizy JL, Glaser S, Francis H and Alpini G: Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology. 35:1329–1340. 2002. View Article : Google Scholar : PubMed/NCBI
13	Gorunova L, Parada LA, Limon J, et al: Non random chromosomal aberrations and cytogenetic heterogeneity in gallbladder carcinomas. Genes Chromosomes Cancer. 26:312–321. 1999. View Article : Google Scholar : PubMed/NCBI
14	Rijken AM, Hu J, Perlman EJ, et al: Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer. 26:185–191. 1999. View Article : Google Scholar : PubMed/NCBI
15	Bullrich F, MacLachlan TK, Sang N, et al: Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res. 55:1199–1205. 1995.PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
17	Dong Z and Cmarik JL: Harvesting cells under anchorage-independent cell transformation conditions for biochemical analyses. Sci STKE. 2002:pl72002.PubMed/NCBI
18	Scherbakov AM, Lobanova YS, Shatskaya VA and Krasil’nikov MA: The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and estrogen receptor signaling. Steroids. 74:535–542. 2009. View Article : Google Scholar : PubMed/NCBI
19	Sasaki K, Tsuno NH, Sunami E, et al: Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
20	Marin JJ, Romero MR and Briz O: Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem. 17:709–740. 2010. View Article : Google Scholar : PubMed/NCBI
21	Heller G, Ziegler B, Brandstetter A, et al: CDK10 is not a target for aberrant DNA methylation in breast cancer. Anticancer Res. 29:3939–3944. 2009.PubMed/NCBI
22	Kolch W: Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837. 2005. View Article : Google Scholar : PubMed/NCBI
23	Beeram M, Patnaik A and Rowinsky EK: Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 23:6771–6790. 2005. View Article : Google Scholar : PubMed/NCBI
24	Small GW, Somasundaram S, Moore DT, Shi YY and Orlowski RZ: Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther. 307:861–869. 2003. View Article : Google Scholar : PubMed/NCBI
25	Dent P and Grant S: Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res. 7:775–783. 2001.
26	Wen SC, Ku DH, De Luca A, Claudio PP, Giordano A and Calabretta B: ets-2 regulates cdc2 kinase activity in mammalian cells: coordinated expression of cdc2 and cyclin A. Exp Cell Res. 217:8–14. 1995. View Article : Google Scholar : PubMed/NCBI
27	Chang F, Steelman LS, Shelton JG, et al: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol. 22:469–480. 2003.PubMed/NCBI